2021 Ranking

Competition is close for top positions

Pharmaceutical companies continue to inch forward in addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index. Pfizer moves into the top five. GSK retains its number one position, yet only slightly ahead of Novartis.

1 GlaxoSmithKline plc
0 1 2 3 4 5
4.59

GlaxoSmithKline plc

Read more
1 Takeda Pharmaceutical Co. Ltd.
0 1 2 3 4 5
4.59

Takeda Pharmaceutical Co. Ltd.

Read more
2 Novartis AG
0 1 2 3 4 5
4.39

Novartis AG

Read more
3 AstraZeneca plc
0 1 2 3 4 5
4.32

AstraZeneca plc

Read more
4 Johnson & Johnson
0 1 2 3 4 5
4.25

Johnson & Johnson

Read more
5 Novo Nordisk A/S
0 1 2 3 4 5
4.12

Novo Nordisk A/S

Read more
5 Pfizer Inc.
0 1 2 3 4 5
4.12

Pfizer Inc.

Read more
6 Roche Holding AG
0 1 2 3 4 5
4.08

Roche Holding AG

Read more
7 Merck KGaA (Merck)
0 1 2 3 4 5
3.75

Merck KGaA (Merck)

Read more
8 Bayer AG
0 1 2 3 4 5
3.55

Bayer AG

Read more
8 Eisai Co. Ltd.
0 1 2 3 4 5
3.55

Eisai Co. Ltd.

Read more
9 Astellas Pharma Inc.
0 1 2 3 4 5
3.46

Astellas Pharma Inc.

Read more
10 Boehringer Ingelheim GmbH
0 1 2 3 4 5
3.28

Boehringer Ingelheim GmbH

Read more
11 Sanofi
0 1 2 3 4 5
3.05

Sanofi

Read more
12 Gilead Sciences Inc.
0 1 2 3 4 5
2.89

Gilead Sciences Inc.

Read more
13 Eli Lilly & Co.
0 1 2 3 4 5
2.85

Eli Lilly & Co.

Read more
14 Merck & Co., Inc. (MSD)
0 1 2 3 4 5
2.80

Merck & Co., Inc. (MSD)

Read more
15 Bristol Myers Squibb Co.
0 1 2 3 4 5
2.70

Bristol Myers Squibb Co.

Read more
16 Daiichi Sankyo Co. Ltd.
0 1 2 3 4 5
2.54

Daiichi Sankyo Co. Ltd.

Read more
17 AbbVie Inc.
0 1 2 3 4 5
2.52

AbbVie Inc.

Read more
0 1 2 3 4 5

The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.


Insights

  • 11 companies view access as a business matter

    More than half companies demonstrate good practice by embedding their access-to-medicine strategy within their overall business strategy and across all therapeutic areas they are involved in. This indicates that access thinking is incorporated consistently within the company. 

  • 12 companies ensure top level accountability

    More than half of the companies provide managers and senior executives with incentives to achieve access-to-medicine goals. Top-level accountability is likely to filter into the rest of the company and can help enable teams within the company to deliver on access-to-medicine initiatives. 

  • Incentives move away from sales targets

    Over half of the companies have incentives that are not wholly linked to sales. By moving away from rewards pegged primarily against sales targets, companies can limit the the risk of misselling (i.e. the act of selling a product to a person when it is not necessary or not adapted for them) or over-selling products.

  • 8 companies stand out for their compliance controls

    Eight companies demonstrate best practice by applying all the compliance controls looked for by the Index, i.e., processes for checking and detecting non-compliance that might negatively affect access to medicine, supported by rigorous monitoring and auditing. 


Get in touch

Back to top |